S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

SHPH Shuttle Pharmaceuticals Holdings Inc

0.595

-0.0434 (-6.80%)

After Hours

Last Updated: 08:19:01

Delayed by 15 minutes

Form 5 - Annual statement of changes in beneficial ownership of securities

Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Shuttle Pharmaceuticals Charts.

Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Shuttle Pharmaceuticals Charts.

Shuttle Pharmaceuticals Holdings Inc News

Form 5/A - Annual statement of changes in beneficial ownership of securities: [Amend]
Friday 7 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 29 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 22 January 2025 (1 month ago) • Edgar (US Regulatory)

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Wednesday 22 January 2025 (1 month ago) • GlobeNewswire Inc.

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments
Tuesday 14 January 2025 (1 month ago) • AllPennyStocks.com

Form 8-K - Current report
Wednesday 8 January 2025 (1 month ago) • Edgar (US Regulatory)

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Wednesday 8 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 20 December 2024 (2 months ago) • Edgar (US Regulatory)

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Friday 20 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 27 November 2024 (3 months ago) • Edgar (US Regulatory)

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
Wednesday 27 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

More Shuttle Pharmaceuticals Holdings Inc News Articles

Australian SE All Ordina...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions